Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes
Valentina Pirro, Kenneth D. Roth, Yanzhu Lin, et al.
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 107, Iss. 2, pp. 363-378
Open Access | Times Cited: 83

Showing 1-25 of 83 citing articles:

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Julio Rosenstock, Juan P. Frías, Ania M. Jastreboff, et al.
The Lancet (2023) Vol. 402, Iss. 10401, pp. 529-544
Closed Access | Times Cited: 213
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 202
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
Michael A. Nauck, David A. D‘Alessio
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 175
Role of branched-chain amino acid metabolism in the pathogenesis of obesity and type 2 diabetes-related metabolic disturbances BCAA metabolism in type 2 diabetes
Froukje Vanweert, Patrick Schrauwen, Esther Phielix
Nutrition and Diabetes (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 140
Insulin resistance and cardiovascular disease
Constantine E. Kosmas, Maria D. Bousvarou, Christina Kostara, et al.
Journal of International Medical Research (2023) Vol. 51, Iss. 3
Open Access | Times Cited: 127
Tirzepatide: First Approval
Yahiya Y. Syed
Drugs (2022) Vol. 82, Iss. 11, pp. 1213-1220
Closed Access | Times Cited: 86
Transforming obesity: The advancement of multi-receptor drugs
Christine M. Kusminski, Diego Pérez–Tilve, Timo D. Müller, et al.
Cell (2024) Vol. 187, Iss. 15, pp. 3829-3853
Closed Access | Times Cited: 24
Tirzepatide: A Review in Type 2 Diabetes
Nicole L. France, Yahiya Y. Syed
Drugs (2024) Vol. 84, Iss. 2, pp. 227-238
Closed Access | Times Cited: 16
Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue
Ricardo J. Samms, Guo‐Fang Zhang, Wentao He, et al.
Molecular Metabolism (2022) Vol. 64, pp. 101550-101550
Open Access | Times Cited: 48
Tirzepatide: A Systematic Update
Imma Forzano, Fahimeh Varzideh, Roberta Avvisato, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 14631-14631
Open Access | Times Cited: 48
Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
Baptist Gallwitz
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 44
Multifaceted Roles of GLP-1 and Its Analogs: A Review on Molecular Mechanisms with a Cardiotherapeutic Perspective
Sudhir Pandey, Supachoke Mangmool, Warisara Parichatikanond
Pharmaceuticals (2023) Vol. 16, Iss. 6, pp. 836-836
Open Access | Times Cited: 26
Evidence that tirzepatide protects against diabetes-related cardiac damages
Fatemeh Taktaz, Lucia Scisciola, Rosaria Anna Fontanella, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 13
Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide
Fatemeh Taktaz, Rosaria Anna Fontanella, Lucia Scisciola, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 13
Targeting systemic inflammation in metabolic disorders. A therapeutic candidate for the prevention of cardiovascular diseases?
Elena Domingo, Patrice Marqués, Vera Francisco, et al.
Pharmacological Research (2024) Vol. 200, pp. 107058-107058
Open Access | Times Cited: 11
Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis
Deep Dutta, Vineet Surana, Rajiv Singla, et al.
Indian Journal of Endocrinology and Metabolism (2021) Vol. 25, Iss. 6, pp. 475-489
Open Access | Times Cited: 43
Weight-centric treatment of type 2 diabetes mellitus
Wissam Ghusn, Maria D. Hurtado, Andrés Acosta
Obesity Pillars (2022) Vol. 4, pp. 100045-100045
Open Access | Times Cited: 29
Novel Antidiabetic Agents and Their Effects on Lipid Profile: A Single Shot for Several Cardiovascular Targets
Francesco Piccirillo, Sara Mastroberardino, Annunziata Nusca, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 10164-10164
Open Access | Times Cited: 21
Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial
Hertzel C. Gerstein, Zhuoru Li, Chinthanie Ramasundarahettige, et al.
Circulation (2023) Vol. 147, Iss. 13, pp. 1004-1013
Open Access | Times Cited: 18
Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity
Isabella Zaffina, Maria Chiara Pelle, Giuseppe Armentaro, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 18
The GIP receptor activates futile calcium cycling in white adipose tissue to increase energy expenditure and drive weight loss in mice
Xinxin Yu, Shiuhwei Chen, Jan‐Bernd Funcke, et al.
Cell Metabolism (2024)
Closed Access | Times Cited: 7
Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence
Salvatore Corrao, C Pollicino, Dalila Maggio, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 6
Therapeutic implications for sphingolipid metabolism in metabolic dysfunction-associated steatohepatitis
Bruno Ramos‐Molina, Joana Rossell, Alejandra Pérez-Montes de, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 5
Weight Loss Therapies and Hypertension Benefits
Vasiliki Katsi, Eleni Manta, Christos Fragoulis, et al.
Biomedicines (2024) Vol. 12, Iss. 10, pp. 2293-2293
Open Access | Times Cited: 5
An overview of obesity‐related complications: The epidemiological evidence linking body weight and other markers of obesity to adverse health outcomes
Matthias Blüher
Diabetes Obesity and Metabolism (2025)
Open Access
Page 1 - Next Page

Scroll to top